| Identification | Back Directory | [Name]
CP-868388 | [CAS]
702681-67-2 | [Synonyms]
CP-868388
(-)-CP-868388
UNII-999KY5ZIGB
CP-868388 free base
(S)-2-(3-(1-((4-Isopropylbenzyloxy)carbonyl)piperidin-3-yl)phenoxy)-2-methylpropanoic acid
2-methyl-2-{3-[(3S)-1-({[4-(propan-2-yl)phenyl]methoxy}carbonyl)piperidin-3-yl]phenoxy}propanoic acid
1-Piperidinecarboxylic acid, 3-[3-(1-carboxy-1-methylethoxy)phenyl]-, 1-[[4-(1-methylethyl)phenyl]methyl] ester, (3S)- | [Molecular Formula]
C26H33NO5 | [MDL Number]
MFCD18452851 | [MOL File]
702681-67-2.mol | [Molecular Weight]
439.54 |
| Chemical Properties | Back Directory | [Boiling point ]
584.6±50.0 °C(Predicted) | [density ]
1.161±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: ≥30mg/mL | [form ]
powder | [pka]
3.28±0.10(Predicted) | [color ]
white to off-white | [Optical Rotation]
[α]/D -50 to -65°, c = 0.2 in methanol | [InChIKey]
CSLFIHDRJSTULR-JOCHJYFZSA-N | [SMILES]
CC(C)c1ccc(COC(=O)N2CCC[C@H](C2)c3cccc(OC(C)(C)C(O)=O)c3)cc1 |
| Safety Data | Back Directory | [Hazard Codes ]
T,N | [Risk Statements ]
25-50/53 | [Safety Statements ]
45-60-61 | [RIDADR ]
UN 2811 6.1 / PGIII | [WGK Germany ]
3 | [Storage Class]
6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | [Hazard Classifications]
Acute Tox. 3 Oral
Aquatic Acute 1
Aquatic Chronic 1 |
| Hazard Information | Back Directory | [Uses]
CP-868388 is a potent PPARα agonist with a Ki of 10.8 nM for therapeutic use as hypolipemics, antidiabetics. | [Biological Activity]
CP-868388 is a potent PPARα agonist with a Ki of 10.8 nM. | [in vivo]
CP-868388 (0-3 mg/kg; oral gavage; once daily; for 2 days; male B6/CBF1J mice) treatment shows a robust and highly significant decrease in circulating plasma triglycerides. Triglyceride lowering is dose-dependent with the greatest efficacy achieved at the 3.0 mg/kg dose, with triglyceride decreases of ~50%[1]. | Animal Model: | Male B6/CBF1J mice[1] | | Dosage: | 0 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg | | Administration: | Oral gavage; once daily; for 2 days | | Result: | Demonstrated a robust and highly significant decrease in circulating plasma triglycerides.
|
| [IC 50]
hPPARα: 10.8 nM (Ki); hPPARγ: 3.47 μM (Ki) |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|